A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)
NCT00001938 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26
Last updated 2020-03-12
Summary
Every cell in the human body contains hundreds of thousands of genes and the proteins made by the genes. Sometimes changes take place in the genes or proteins that may make the cells more likely to develop into cancer. An experimental protein profile test that finds these changes may be able to provide information about whose cancer will stay in remission and whose will return.
Volunteer patients whose epithelial ovarian cancer is in remission are eligible for this study. Specimens will be collected from blood, saliva, and urine for the first protein profile test. Sample sets for more protein profile tests will be collected at follow-up visits 1 month and 3 months later and every 3 months afterward. If and when the cancer returns, an additional sample set will be obtained and a biopsy of the relapsed tumor will be taken both for a protein profile test and for review of the function and structure of the disease (pathology review). The protein profiles from these samples will be compared to those samples already collected to detect protein pattern changes. The amount of lysophosphatidic acid (LPA) in the blood, a sign of ovarian cancer, will also be measured to see if LPA is useful in detecting the return of ovarian cancer.
If patients get fluid in the stomach or chest, it will be tested for cancer cells and proteins made by the tumor. If a physical exam or CT scan indicates a possible return of the cancer, a biopsy will be performed and a sample saved for a protein profile.
Conditions
- Ovarian Neoplasm
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Elise C Kohn, M.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-04-24
- Primary Completion
- 2012-12-31
- Completion
- 2020-03-10
Countries
- United States
Study Locations
More Related Trials
-
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
NCT00898781 ·Status: TERMINATED
-
New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence
NCT05410028 ·Status: RECRUITING
-
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
NCT01034033 ·Status: RECRUITING
-
Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma
NCT01062438 ·Status: COMPLETED
-
Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer
NCT03622385 ·Status: COMPLETED
-
Ovarian Cancer Hemoscope Trial
NCT02811224 ·Status: ACTIVE_NOT_RECRUITING
-
DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers
NCT01139983 ·Status: COMPLETED
-
SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer
NCT00900042 ·Status: COMPLETED
-
Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC
NCT02436772 ·Status: COMPLETED
-
Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer
NCT00897845 ·Status: COMPLETED
-
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663 ·Status: COMPLETED
-
Community Cancer Centers Pilot Patient Survey
NCT00786656 ·Status: COMPLETED
-
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
NCT00002695 ·Status: COMPLETED
-
Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma
NCT01807143 ·Status: COMPLETED
-
Retrospective Study of Ovarian Cancer Patients With Brain Metastasis
NCT01258881 ·Status: UNKNOWN
-
Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer
NCT04454450 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study
NCT00323726 ·Status: WITHDRAWN
-
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
NCT05212779 ·Status: ACTIVE_NOT_RECRUITING
-
Collecting and Storing Blood Samples From Patients With Cancer
NCT00900120 ·Status: WITHDRAWN
-
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
NCT05600933 ·Status: ENROLLING_BY_INVITATION
-
DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma
NCT01190943 ·Status: COMPLETED
-
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
NCT03614689 ·Status: ACTIVE_NOT_RECRUITING
-
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer
NCT02470819 ·Status: WITHDRAWN ·Phase: NA
-
Biopsies of Cancer Patients for Tumor Molecular Characterization
NCT01061944 ·Status: COMPLETED
-
Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.
NCT05458973 ·Status: UNKNOWN